Registration

Mr. Xu focuses primarily on the biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and RareStoneGroup. Other companies Chong has held board positions also including OnCusp Therapeutics, Sironax, Semma Therapeutics, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a consultant at McKinsey, a hedge fund healthcare equity analyst, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Jing-Ke Weng is the Inaugural Director of the Institute for Plant-HumanInterface, a Professor of Chemistry, Chemical Biology, and Bioengineering, and an Affiliated Professor of Chemical Engineering at Northeastern University. Prior to joining Northeastern, he was a member of the Whitehead Institute and was an Assistant Professor, and Associate Professor of Biology at MIT(2013-2023). He received his B.S. (2003) in Biotechnology from Zhejiang University, and his Ph.D. (2009) in Biochemistry, from Purdue University. He was a Pioneer Postdoctoral Fellow at the Salk Institute and Howard Hughes Medical Institute (2009-2013). Dr. Weng has won numerous awards in his career, including the Beckman Young Investigator Award (2016), Alfred P. Sloan Research Fellow (2016), Searle Scholar (2015), Pew Scholar in the biomedical Sciences (2014), American Society of Plant Biologists Early CareerAward (2014), and Tansley Medal for Excellence in Plant Science (2013). Dr.Weng has also served as a co-founder or scientific advisor for multiple biotech companies.

Dr. Dong Kong received his postdoctoral training at the Division of Endocrinology, Beth Israel Deaconess Medical Center, and at the Department of Neurobiology of Harvard Medical School. He is an associated member of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital, and the Broad Institute of MIT and Harvard. He is also an adjunct professor of neuroscience at Tuft University School of Medicine. Dr. Kong’s research group is focusing on neuron-metabolism and leveraging a battery of cutting-edge technologies, ranging from genetically engineered mouse models, recombinant viral vectors and viral tracing systems, optogenetic and pharmacogenetic approaches, and patch-clamp electrophysiology.

Hongkai He is a General Partner at Taihill Venture, a pre-seed deep tech firm based in Boston. With a specialization in disruptive technology, Hongkai has invested in over 100 US startups since 2017, including notable companies such as KulaBio, Lightelligence (unicorn), Revela (acquired), Xtalpi (unicorn), Cider (unicorn), Butlr, CacheDNA, Axoft, Databento, and CardeaBio(acquired). Taihill Venture has been recognized as one of the '2021 China’sTOP10 Investment Firms in Overseas Market' by 36Kr. In addition to his role at Taihill Venture, Hongkai contributes as a mentor at Techstars, Newchip, TCN, and Neonvest. As a graduate of Columbia University, he is a repeat founder with a background in mathematics and supercomputing.

Jianzhu Chen is a member of the Koch Institute for Integrative Cancer Research, Professor of Biology at MIT, and an Associate Member of the Broad Institute. He is also a Principal Investigator at the Antimicrobial Resistance Interdisciplinary Research Group at the Singapore-MIT Alliance for Research and Technology (SMART). He earned his bachelor’s degree from Wuhan University in China and a PhD degree from Stanford University, where he started immunological research in the laboratory of Leonard and LeonoreHerzenberg. He was a postdoctoral fellow with Frederick Alt, initially at Columbia University and then at Boston Children’s Hospital, where he was supported by the Cancer Research Institute Postdoctoral Fellowship and Arthritis Investigator Award. He was an Instructor at Harvard Medical School before joining the MIT faculty in the Department of Biology in 1994. He has made significant contributions to a broad area of research in immunology, cancer research, infectious diseases, and animal models of human diseases. His research has been recognized by Cheryl Witlock Memorial Prize, Harcourt General Charitable Foundation New Investigator Award, and Latham FamilyCareer Development Award.